Metric Finance
LearnFAQ
LearnFAQ

Learn / KOD

NASDAQ: KOD

Kodiak Sciences (KOD) stock, explained like you're 5

Kodiak Sciences trades on the Nasdaq under the ticker KOD. It is a mid cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 6.3 billion dollars.

Ticker
KOD
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Mid cap, about 6.3 billion dollars

Is Kodiak Sciences a small, medium or large cap company?

No. Kodiak Sciences is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 6.3 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Kodiak Sciences makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves KOD stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • KOD Nov 2026 130.000 put (KOD261120P00130000) stock price, news, quote and history (Yahoo Finance UK)
  • How Investors May Respond To Kodiak Sciences Stock After Wet AMD Trial Success (Simply Wall Street)
  • KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations (Timothy Sykes)
  • Discipline and Rules Based Execution in KOD Response (Stock Traders Daily)
  • Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial (Forbes)

Follow KOD in your daily brief

Each trading day at 5 PM ET we post what happened to Kodiak Sciences and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow KOD

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Kodiak Sciences stock

What does Kodiak Sciences do?

Kodiak Sciences trades on the Nasdaq under the ticker KOD. It is a mid cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 6.3 billion dollars.

What is the ticker symbol for Kodiak Sciences?

Kodiak Sciences trades under the ticker KOD on the Nasdaq.

What is Kodiak Sciences's market cap?

Kodiak Sciences is a mid cap stock with a market cap of about 6.3 billion dollars.

How does Kodiak Sciences make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves KOD stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow KOD stock every day?

Add KOD to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow KOD daily

A free brief on Kodiak Sciences and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare KOD: KOD vs ARGX, KOD vs RVMD, KOD vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed